Abstracts
2019
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes
E. Maddaloni, R.L. Coleman, O.F. Agbaje, R. Buzzetti, R.R. Holman
Diabetologia 2019;62:(Supp 1):S115
[Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model
R.L. Coleman, A.M. Gray, D.K. McGuire, R.R. Holman
Diabetologia 2019;62:(Supp 1):S152
[Abstract]
2018
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults: results from the UKPDS
E. Maddaloni, R.L. Coleman, P. Pozzilli, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S574-5
[Abstract]
Risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults: results from the UKPDS
E. Maddaloni, R.L. Coleman, P. Pozzilli, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S574-5
[Abstract]
2008
Diabetes UK Annual Professional Conference, Glasgow
The UKPDS Life Expectancy Calculator for Individuals with Type 2 diabetes
Price HC, Kennedy I, Clarke PM, Gray AM and Holman RR.
Diabetic Medicine 2008;25:suppl 1:63
[Abstract]
The UKPDS Life Expectancy Calculator for Individuals with Type 2 diabetes
Price HC, Kennedy I, Clarke PM, Gray AM and Holman RR.
Diabetic Medicine 2008;25:suppl 1:63
[Abstract]
44th Annual Meeting of the European Association for the Study of Diabetes, Rome
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ
Diabetologia 2008;51:Suppl 1:S549
[Abstract]
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ
Diabetologia 2008;51:Suppl 1:S549
[Abstract]
2007
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
Does metformin prevent cardiovascular events?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S26
[Abstract]
Does metformin prevent cardiovascular events?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S26
[Abstract]
2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
The expanding evidence base - what have we added to our understanding of diabetes disease modification?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S43-S44
[Abstract]
The expanding evidence base - what have we added to our understanding of diabetes disease modification?
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S43-S44
[Abstract]
67th Scientific Session of the American Diabetes Association, Chicago
The Oxford Risk Engine: A Cardiovascular Risk Calculator for Individuals with or without Type 2 diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2007;56:Suppl 1:A170
[Abstract]
The Oxford Risk Engine: A Cardiovascular Risk Calculator for Individuals with or without Type 2 diabetes
Coleman RL, Stevens RJ, Holman RR
Diabetes 2007;56:Suppl 1:A170
[Abstract]
The Diabetes UK Annual Professional Conference, Glasgow
Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2007;24:Suppl 1:56
[Abstract]
Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2007;24:Suppl 1:56
[Abstract]
2006
66th Scientific Session of the American Diabetes Association, Washington
Estimating Risk of Clinically Evident Retinopathy in Type 2 Diabetes.
Coleman RL, Stevens RJ, Aldington SJ, Holman RR
Diabetes 2006;55:Suppl 1:A53
Estimating Risk of Clinically Evident Retinopathy in Type 2 Diabetes.
Coleman RL, Stevens RJ, Aldington SJ, Holman RR
Diabetes 2006;55:Suppl 1:A53
2005
41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A32
Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A32
41st Annual Meeting of the European Association for the Study of Diabetes, Athens
FPG and HbA1c are independent risk factors for microvascular but not macrovascular complications in newly diagnosed type 2 diabetes
Kim JI, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A33
[Abstract]
FPG and HbA1c are independent risk factors for microvascular but not macrovascular complications in newly diagnosed type 2 diabetes
Kim JI, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A33
[Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Relationship of autoantibodies to glutamic acid decarboxylase (GADA) to deterioration of glycamic control assessed by therapy progression in latent autoimmune diabetes in adults (LADA) in the UKPDS
Clark A, Desai M, Cull CA, Horton VA, Christie MR, Bingley PJ, Bonifacio E, Levy JC, Holman RR
Diabetologia 2005;48:Suppl 1:A86
[Abstract]
Relationship of autoantibodies to glutamic acid decarboxylase (GADA) to deterioration of glycamic control assessed by therapy progression in latent autoimmune diabetes in adults (LADA) in the UKPDS
Clark A, Desai M, Cull CA, Horton VA, Christie MR, Bingley PJ, Bonifacio E, Levy JC, Holman RR
Diabetologia 2005;48:Suppl 1:A86
[Abstract]
41st Annual Meeting of the European Association for the Study of Diabetes, Athens
Genotype and beta cell response to therapy in a large type 2 diabetic cohort
Powell BL, Stratton IM, Holman RR, McCarthy MI
Diabetologia 2005;48:Suppl 1:A101-A102
[Abstract]
Genotype and beta cell response to therapy in a large type 2 diabetic cohort
Powell BL, Stratton IM, Holman RR, McCarthy MI
Diabetologia 2005;48:Suppl 1:A101-A102
[Abstract]
2004
40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A42
Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
Coleman RL, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A42
40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
Stevens RJ, Coleman RL, Shine BL, Holman RR
Diabetologia 2004;47:Suppl 1:A61
[Abstract]
Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
Stevens RJ, Coleman RL, Shine BL, Holman RR
Diabetologia 2004;47:Suppl 1:A61
[Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Risk factors for neuropathy in UKPDS
Stratton IM, Holman RR, Boulton AJM
Diabetologia 2004;47:Suppl 1:A47
[Abstract]
Risk factors for neuropathy in UKPDS
Stratton IM, Holman RR, Boulton AJM
Diabetologia 2004;47:Suppl 1:A47
[Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich
GAD65 autoantibody titres at diagnosis in Latent Autoimmune Diabetes in Adults (LADA) differ from Type 1 diabetes (T1D) and together with epitope specificity predict insulin requirement
Desai M, Williams AJK, Horton VA, Bingley PJ, Levy JC, Cull CA, Holman RR, Bonifacio E, Christie MR, Clark A
Diabetologia 2004;47:Suppl 1:A186
[Abstract]
GAD65 autoantibody titres at diagnosis in Latent Autoimmune Diabetes in Adults (LADA) differ from Type 1 diabetes (T1D) and together with epitope specificity predict insulin requirement
Desai M, Williams AJK, Horton VA, Bingley PJ, Levy JC, Cull CA, Holman RR, Bonifacio E, Christie MR, Clark A
Diabetologia 2004;47:Suppl 1:A186
[Abstract]
40th Annual Meeting of the European Association for the Study of Diabetes, Munich
Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
Clarke PM, Gray A, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A50
[Abstract]
Cost utility analysis of intensive blood-glucose control, tight blood pressure control and metformin in patients with Type 2 diabetes
Clarke PM, Gray A, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A50
[Abstract]
2002
62nd Scientific Sessions of the American Diabetes Association, San Francisco
Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Holman RR
Diabetes 2002;51:Suppl 2:A172
Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Holman RR
Diabetes 2002;51:Suppl 2:A172
2001
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Cull CA, Wright AD, Macleod KM, Holman RR
Diabetologia 2001;44:Suppl 1:A217
[Abstract]
Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Cull CA, Wright AD, Macleod KM, Holman RR
Diabetologia 2001;44:Suppl 1:A217
[Abstract]
37th Annual Meeting of the European Association for the Study of Diabetes, Glasgow
Autoantibodies to IA2ic and to Phogrin increase the prediction for insulin requirement in patients with Type 2 Diabetes
Bosi E, Locatelli M, Cull CA, Scirpoli M, Bonifacio E, Stratton IM, Holman RR, Bottazzo GF
Diabetologia 2001;44:Suppl 1:A103
[Abstract]
Autoantibodies to IA2ic and to Phogrin increase the prediction for insulin requirement in patients with Type 2 Diabetes
Bosi E, Locatelli M, Cull CA, Scirpoli M, Bonifacio E, Stratton IM, Holman RR, Bottazzo GF
Diabetologia 2001;44:Suppl 1:A103
[Abstract]
2000
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Cull CA, Wright AD, Holman RR
Diabetologia 2000;43:Suppl 1:A40
[Abstract]
Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Cull CA, Wright AD, Holman RR
Diabetologia 2000;43:Suppl 1:A40
[Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
ApoE ε2 and butyrylcholinesterase K variant are associated with coronary heart disease in type 2 diabetes
Horton VA, Groves CJ, Naylor M, Owen R, Wiltshire S, Stratton IM, Green F, Holman RR
Diabetologia 2000;43:Suppl 1:A86
[Abstract]
ApoE ε2 and butyrylcholinesterase K variant are associated with coronary heart disease in type 2 diabetes
Horton VA, Groves CJ, Naylor M, Owen R, Wiltshire S, Stratton IM, Green F, Holman RR
Diabetologia 2000;43:Suppl 1:A86
[Abstract]
36th Annual Meeting of the European Association for the Study of Diabetes, Jerusalem
Standardised HbA1c measurements are essential for the management of glycaemia as a risk factor in diabetes
Manley SE, Holman RR
Diabetologia 2000;43:Suppl 1:A232
[Abstract]
Standardised HbA1c measurements are essential for the management of glycaemia as a risk factor in diabetes
Manley SE, Holman RR
Diabetologia 2000;43:Suppl 1:A232
[Abstract]
1998
34th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Paraoxonase polymorphism MET-LEU 54 is associated with fatal myocardial infarction in type 2 diabetic patients
Groves CJ, Horton VA, Ritchie A, Owen RJ, Stratton IR, Green FR, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A115
[Abstract]
Paraoxonase polymorphism MET-LEU 54 is associated with fatal myocardial infarction in type 2 diabetic patients
Groves CJ, Horton VA, Ritchie A, Owen RJ, Stratton IR, Green FR, Holman RR, Turner RC
Diabetologia 1998;41:Suppl 1:A115
[Abstract]
